Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBT-3627 in Healthy Volunteers and Parkinson's Disease
NCT06466525Phase 1Recruiting
- Sponsor
- Longevity Biotech
- Start
- Jul 2024
- Primary completion
- Feb 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of LBT-3627 in Parkinson's disease (PD) (3 arms), sponsored by Longevity Biotech. Primary endpoint: Adverse Events at 4 weeks. Started Jul 2024; status: recruiting.
02
Drugs
LBT-3627
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06466525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466525.